Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH)
- 1.5k Downloads
Philadelphia-negative myeloproliferative neoplasms (Ph-negative MPN) comprise a heterogeneous group of chronic hematologic malignancies. The quality of life, morbidity, and mortality of patients with MPN are primarily affected by disease-related symptoms, thromboembolic and hemorrhagic complications, and progression to myelofibrosis and acute leukemia. Major bleeding represents a common and important complication in MPN, and the incidence of such bleeding events will become even more relevant in the future due to the increasing disease prevalence and survival of MPN patients. This review discusses the causes, differential diagnoses, prevention, and management of bleeding episodes in patients with MPN, aiming at defining updated standards of care in these often challenging situations.
KeywordsMPN Myeloproliferative neoplasms Bleeding Hemorrhage Management Essential thrombocythemia Polycythemia vera Review
Compliance with ethical standards
Conflict of interest
GB received honoraria and travel grants from Bristol Myers Squibb, Novartis, Sanofi, and Merck.
KS is a member of the Advisory Board of Novo Nordisk and a travel support of Bayer.
TB received honoraria for participation in satellite symposia and advisory boards and research support from Novartis.
AT received research funding, honoraria for consultancy, and travel support from Baxter, Bayer, Biotest, Boehringer Ingelheim, CSL Behring, Leo Pharma, Novo Nordisk, Octapharma, and Pfizer.
AM is a consultant of Leo Pharma and Roche, has equity ownership of Bayer and Roche, and a recipient of research funding from Leo Pharma; honoraria and travel grants from Amgen, Aspen Germany, Boehringer Ingelheim, Behring, Bristol-Myers Squibb, GlaxoSmithKline, Leo Pharma, Novartis, and Roche (patents and royalties: not applicable); and membership on an entity’s Board of Directors or advisory committees of Bristol-Myers Squibb and Leo Pharma.
HR is a member of Consultancy and Advisory Boards of Aspen, Baxalta, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Leo-Pharma, Novartis, Pfizer, Sanofi, and Shire.
SK a member of Consultancy and Advisory Boards of Ariad, AOP, Baxalta, Bristol-Myers Squibb, CTI, Novartis, Pfizer, and Sanofi. He received research funding (Novartis and Novartis Foundation) and honoraria and travel grants (Ariad, Alexion, AOP, Baxalta, Bristol-Myers Squibb, Celgene, CTI, Novartis, Pfizer, Sanofi, Shire).
- 1.Swerdlow SH, International Agency for Research on C, World Health O (2008) WHO classification of tumours of haematopoietic and lymphoid tissues: International Agency for Research on CancerGoogle Scholar
- 19.Tiede A, Klamroth R, Scharf RE, et al (2014) Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. BloodGoogle Scholar
- 24.Michiels JJ, De Raeve H, Berneman Z et al (2006) The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders. Semin Thromb Hemost 32(4 Pt 2):307–340PubMedCrossRefGoogle Scholar
- 26.Petro E. Petrides GMB, Heinz Gisslinger, Martin Grießhammer, Eva Lengfelder (2014) Essentielle (oder primaere) Thrombozythaemie. DGHO Leitlinien OnkopediaGoogle Scholar
- 29.Laffan MA, Lester W, O’Donnell JS et al (2014) The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British committee for standards in haematology. Br J Haematol 167(4):453–465PubMedPubMedCentralCrossRefGoogle Scholar
- 33.Mannucci PMPAK PA, Schulman S, Di Paola J, Schneppenheim R, Cox Gill J (2013) Prophylactic efficacy and pharmacokinetically guided dosing of a von Willebrand factor/factor VIII concentrate in adults and children with von Willebrand’s disease undergoing elective surgery: a pooled and comparative analysis of data from USA and European Union clinical trials. Blood Transfusion 4:533–540Google Scholar
- 35.Leissinger C, Becton D, Cornell C Jr, Cox GJ (2001) High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A. Haemophilia 7(3):258–266PubMedCrossRefGoogle Scholar
- 52.Bjorn ME, Holmstrom MO, Hasselbalch HC (2015) Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: a report on 12 Danish patients. Leuk Lymphoma. 2015:1–4Google Scholar
- 73.Kreher S, Ochsenreither S, Trappe RU et al (2014) Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the haemostasis working party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (OGHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.). Ann Hematol 93(12):1953–1963PubMedCrossRefGoogle Scholar
- 74.Schulman S, Beyth RJ, Kearon C, Levine MN, American College of Chest P (2008) Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133(6 Suppl):257S–298SPubMedCrossRefGoogle Scholar
- 82.Hanken H, Grobe A, Heiland M, et al (2015) Postoperative bleeding risk for oral surgery under continued rivaroxaban anticoagulant therapy. Clin Oral InvestigGoogle Scholar
- 83.Andras A, Sala Tenna A, Crawford F (2012) Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism. Cochrane Database Syst Rev; 10:CD002001Google Scholar
- 84.Laporte S, Bertoletti L, Romera A, Mismetti P, de Llano LA P, Meyer G (2012) Long-term treatment of venous thromboembolism with tinzaparin compared to vitamin K antagonists: a meta-analysis of 5 randomized trials in non-cancer and cancer patients. Thromb Res 130(6):853–858PubMedCrossRefGoogle Scholar
- 105.Bejanyan N, Tiu RV, Raza A et al (2012) A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF). Cancer 118(16):3968–3976PubMedCrossRefGoogle Scholar
- 106.Link CS, Platzbecker U, Kroschinsky F et al (2013) Association of oesophageal varices and splanchnic vein thromboses in patients with JAK2-positive myeloproliferative neoplasms: presentation of two cases and data from a retrospective analysis. Case Rep Oncol 6(2):311–315PubMedPubMedCentralCrossRefGoogle Scholar